Sesha Sai Nikhil Chintalapati has disclosed the acquisition of equity shares in Novelix Pharmaceuticals Limited under SEBI's substantial acquisition regulations, marking a significant increase in his shareholding through preferential allotment.

Share Acquisition Details

The acquisition involved 4,92,000 equity shares obtained through preferential allotment on December 24, 2025. This transaction was disclosed in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Pattern Changes

The acquisition resulted in a substantial change in Chintalapati's shareholding position in the pharmaceutical company. His voting rights percentage increased significantly following this transaction.

Company Capital Structure

Post-acquisition, Novelix Pharmaceuticals' capital structure reflects the expanded equity base. The company maintains a substantial warrant component in its diluted capital structure.

Persons Acting in Concert

The disclosure also identifies DM Fincon Services LLP as a person acting in concert (PAC) with the acquirer. DM Fincon Services LLP holds 20,000 shares representing 0.12% voting rights and 0.08% of total voting capital, with no change in their position during this acquisition.

Regulatory Compliance

The disclosure was made pursuant to SEBI regulations governing substantial acquisitions, ensuring transparency in shareholding changes above prescribed thresholds. The acquirer has fulfilled all mandatory disclosure requirements under the applicable regulations, providing detailed information about the transaction and resulting shareholding pattern to BSE Limited where the company's shares are listed under scrip code 536565.

Trimurthi has successfully allotted 10,74,000 equity shares upon conversion of warrants, marking a significant capital raising exercise for the pharmaceutical company. The board of directors approved this allotment during their meeting held on December 24, 2025, at the company's registered office in Hyderabad.

Share Allotment Details

The company allotted equity shares with the following specifications:

The shares were issued upon exercising the option available with warrant holders, who had previously paid ₹15.00 per warrant representing 75% of the issue price. These warrants were part of 1,50,00,000 warrants originally allotted on January 10, 2025, on a preferential basis.

Investor Allocation

The allotment was distributed among four strategic investors, comprising both promoter and non-promoter categories:

The allotment represents conversion of 10,74,000 warrants out of the total 1,50,00,000 warrants issued, with 61,91,000 warrants having been converted previously.

Impact on Share Capital

Following this allotment, the company's capital structure has been strengthened significantly:

This represents an increase of ₹1,07,40,000 in the paid-up equity capital, reflecting the company's successful capital expansion through the warrant conversion mechanism.

Regulatory Compliance

The allotment was conducted in full compliance with regulatory requirements. The company had received in-principle approval from BSE Limited on December 31, 2024, and the original warrant issuance was approved through a special resolution passed by shareholders at an Extra-Ordinary General Meeting held on November 18, 2024. The disclosure has been made as per Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring complete transparency in the capital raising process.

The recent allotment of 10.74 lakh equity shares at ₹20 each upon warrant conversion has raised ₹2.15 crores for Trimurthi. This move has increased the company's paid-up capital to ₹17.22 crores, further strengthening its financial position.